PMC10023944_01
The clinical course of the present case is presented here. The patient's blood TG concentration and LDL-Cho is presented in the graph. The laboratory data is presented in the table below. Day 1 of the graph indicates the day when the patient was first administered with the ABVD regimen. ABVD regimen: doxorubicin, bleomycin, vinblastine, and dacarbazine combination therapy. Concomitant drugs were trimethoprim-sulfamethoxazole combination, fluconazole, esomeprazole, and febuxostat. TG: triglyceride; T-Bil: Total bilirubin; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; gamma-GTP: gamma-glutamyl transpeptidase; LDL-Cho: low-density lipoprotein cholesterol; HDL-Cho: High-density lipoprotein cholesterol; AMY: Amylase; Na: Sodium.
gr1.jpg
PMC10023944_01_gr1.jpg
fig0001
On day -40, the fasting serum triglyceride (295 mg/dL) and low-density lipoprotein cholesterol (LDL-Cho; 219 mg/dL) levels were higher than normal at baseline (Fig. 1). Fig. 1 depicts the clinical course of the patient. DXR, 10 mg/m2 BLM, 6 mg/m2 VBL, and 375 mg/m2 DTIC IV) on days 1 and 15, with repeated cycles every 28 days for classical Hodgkin lymphoma (Fig. 1. Day 1). On day 58 (Fig. 1), the fasting blood TG concentration increased to grade 4 (1451 mg/dL).